Study Establishes XOMA's XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In Vivo Mar 08, 2012 8:01am EST
XOMA to Announce Fourth Quarter and Year-End 2011 Financial Results and Host Webcast Conference Call on March 14 Mar 07, 2012 4:05pm EST
XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants Mar 06, 2012 9:00am EST
XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations Jan 17, 2012 4:05pm EST
